EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐ PD ‐ L1 or anti‐ PD1 ) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital

Danainut Naratornsirakul, Busyamas Chewaskulyong iD, Sarawut Kongkarnka, Songporn Oranratnachai iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70007 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Danainut Naratornsirakul und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Immune Checkpoint Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite promising outcomes of first‐line immunotherapy with or without chemotherapy in advanced non‐small cell lung cancer (NSCLC), limited accessibility due to reimbursement was remain the problem in low to middle income countries. This study aimed to evaluate real‐world effectiveness of immunotherapy in patients with advanced NSCLC in Northern Thailand.

Method

A retrospective, single‐centered cohort, was conducted. Patients with advanced NSCLC who underwent PD‐L1 testing (excluding EGFR and ALK mutations) and were treated with immunotherapy or without chemotherapy or chemotherapy alone were included. The primary end point was progression‐free survival (PFS). The secondary endpoints were overall survival (OS), objective response rate (ORR), and adverse events.

Results

A total of 123 patients, of which 21 patients received immunotherapy‐based regimen and 102 patients received chemotherapy alone. The median PFS was 11.9 months in immunotherapy‐based group compared to 5.93 months in the chemotherapy group, with a. hazard ratio (HR) of 0.4 (95% confidence interval [CI], 0.23 to 0.68; p = 0.001). Similarly, the median OS was 26.68 months in the immunotherapy‐based group and 11.21 months in the chemotherapy group, with HR of 0.42 (95% CI 0.22–0.8; p = 0.009). ORRs were significantly higher in the immunotherapy‐based group, with 65% of patients showing a response compared to 32% in the chemotherapy group ( p = 0.006).

Conclusion

The result of this real‐world study in patients with advanced stage NSCLC indicate that first‐line immunotherapy‐based regimen was associated with significantly greater PFS, OS, and ORR with a safety profile consistent with pivotal studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungImmune Checkpoint InhibitorsLung NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedB7-H1 AntigenImmunotherapyProgrammed Cell Death 1 ReceptorProgression-Free SurvivalRetrospective StudiesTertiary Care CentersThailandTreatment Outcome

Stichwörter der Autor:innen

anti‐PD‐L1anti‐Pd1 immunotherapyimmunotherapynon‐small cell lung cancer

Substanzen

B7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
  • Sriphat Medical Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.

ORCID-Profile: Busyamas Chewaskulyong, Songporn Oranratnachai

Zitieren

APA

Naratornsirakul, D., Chewaskulyong, B., Kongkarnka, S., & Oranratnachai, S. (2024). Comparison of treatment outcome between first‐line combination immunotherapy (anti‐ PD ‐ L1 or anti‐ PD1 ) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital. Cancer Medicine. https://doi.org/10.1002/cam4.70007

Vancouver

Naratornsirakul D, Chewaskulyong B, Kongkarnka S, Oranratnachai S. Comparison of treatment outcome between first‐line combination immunotherapy (anti‐ PD ‐ L1 or anti‐ PD1 ) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital. Cancer Medicine. 2024. doi:10.1002/cam4.70007

BibTeX
@article{Naratornsirakul2024,
  author = {Naratornsirakul, Danainut and Chewaskulyong, Busyamas and Kongkarnka, Sarawut and Oranratnachai, Songporn},
  title = {Comparison of treatment outcome between first‐line combination immunotherapy (anti‐ PD ‐ L1 or anti‐ PD1 ) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70007}
}
Kostenlos starten →